Kineta Four LLC
Records under this name other than patents Kineta Four LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,498,470 | Antiviral Drugs for Treatment of Arenavirus Infection Formerly held In force · High confidence | In force | High confidence | |
| US 10,000,486 | Antiviral Drugs for Treatment of Arenavirus Infection Formerly held In force · High confidence | In force | High confidence | |
| US 9,067,873 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Lapsed on the fee record Ended Jun 30, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jun 30, 2023 | From the USPTO record |
| US 8,754,082 | Antiviral drugs for treatment of Arenavirus infection Lapsed on the fee record Ended Jun 17, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 17, 2022 | From the USPTO record |
| US 8,461,177 | Antiviral drugs for treatment of arenavirus infection Lapsed on the fee record Ended Jun 11, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jun 11, 2021 | From the USPTO record |
| US 8,410,149 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Lapsed on the fee record Ended Apr 2, 2021 · From the USPTO record | Lapsed on the fee record | Ended Apr 2, 2021 | From the USPTO record |
| US 8,148,428 | Antiviral drugs for treatment of arenavirus infection Lapsed on the fee record Ended Apr 3, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2020 | From the USPTO record |
| US 8,106,058 | Anti-arenaviral compounds Lapsed on the fee record Ended Jan 31, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 31, 2020 | From the USPTO record |
| US 9,199,920 | Antiviral drugs for treatment of arenavirus infection Lapsed on the fee record Ended Dec 1, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 1, 2019 | From the USPTO record |
| US 9,115,065 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses Lapsed on the fee record Ended Aug 25, 2019 · From the USPTO record | Lapsed on the fee record | Ended Aug 25, 2019 | From the USPTO record |